{"id":745117,"date":"2015-09-21T07:00:00","date_gmt":"2015-09-21T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/"},"modified":"2025-11-07T01:24:56","modified_gmt":"2025-11-07T06:24:56","slug":"data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/","title":{"rendered":"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: &#8230;"},"content":{"rendered":"<p class=\"bwalignc\">       &#8230;Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma        and Biliary Tract Cancer     <\/p>\n<p class=\"bwalignc\">       Data to Include First-Time Findings on the Potential Importance of        PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1        Therapy     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that new data investigating the anti-tumor activity of<br \/>\n      KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab) across a broad range of advanced<br \/>\n      cancers will be presented at this year\u2019s European Cancer Congress (ECC)<br \/>\n      in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts<br \/>\n      across nine difficult-to-treat cancers will be presented at this year\u2019s<br \/>\n      ECC \u2013 including four late-breaking oral presentations. First-time data<br \/>\n      looking at PD-L2 expression in multiple tumors to assess the potential<br \/>\n      value of this biomarker in patient responsiveness to anti PD-1 therapies<br \/>\n      will also be presented. With these and other presentations, data on the<br \/>\n      potential role of KEYTRUDA will have been presented in more than 17<br \/>\n      different cancers.\n    <\/p>\n<p>\n      Studies accepted into this year\u2019s ECC program also include the<br \/>\n      investigation of KEYTRUDA monotherapy in anal cancer, biliary tract<br \/>\n      cancer, colorectal cancer, Merkel cell carcinoma (a type of skin<br \/>\n      cancer), nasopharyngeal carcinoma (a type of head and neck cancer), and<br \/>\n      non-small cell lung cancer (NSCLC), as well as a study evaluating<br \/>\n      KEYTRUDA in combination with another immunotherapy treatment in melanoma.\n    <\/p>\n<p>\n      \u201cAs we continue to build our growing body of clinical data expanding our<br \/>\n      understanding of the potential for KEYTRUDA, we are also committed to<br \/>\n      identifying factors that may help us determine which patients are most<br \/>\n      likely to respond best to an individual medicine or approach,\u201d said Dr.<br \/>\n      Roger Dansey, senior vice president and therapeutic area head, oncology<br \/>\n      late-stage development, Merck Research Laboratories. \u201cThe initial data<br \/>\n      we are seeing with regard to PD-L2 expression now point to the potential<br \/>\n      relevance of dual PD-L1 and PD-L2 blockade in anti-PD-1 therapy for<br \/>\n      cancer treatment.\u201d\n    <\/p>\n<p>\n      KEYTRUDA, Merck\u2019s anti-PD-1 therapy, is a humanized monoclonal antibody<br \/>\n      that blocks the interaction between PD-1 and its ligands, PD-L1 and<br \/>\n      PD-L2. By binding to the PD-1 receptor and blocking the interaction with<br \/>\n      the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated<br \/>\n      inhibition of the immune response, including the anti-tumor immune<br \/>\n      response. The KEYTRUDA clinical development program has rapidly expanded<br \/>\n      to encompass more than 30 tumor types in more than 130 clinical trials,<br \/>\n      of which more than 70 trials combine KEYTRUDA with other cancer<br \/>\n      treatments. Registration-enabling trials of KEYTRUDA monotherapy are<br \/>\n      currently enrolling patients in melanoma, NSCLC, head and neck cancer,<br \/>\n      bladder cancer, gastric cancer, colorectal cancer, and Hodgkin Lymphoma,<br \/>\n      with further trials in planning for other cancers.\n    <\/p>\n<p>\n      \u201cAt Merck, we are rapidly expanding our clinical studies for KEYTRUDA in<br \/>\n      a wide range of cancers with the goal of potentially providing cancer<br \/>\n      patients with promising new options, and helping physicians identify<br \/>\n      which approaches may be best for an individual patient,\u201d said Dr. Roy<br \/>\n      Baynes, senior vice president and head of global clinical development,<br \/>\n      Merck Research Laboratories. \u201cWe look forward to sharing these new data<br \/>\n      at the European Cancer Congress as we continue to focus on bringing the<br \/>\n      breakthrough science of immuno-oncology to as many patients as possible.\u201d\n    <\/p>\n<p>\n      Merck\u2019s Immuno-Oncology Data at European Cancer Congress 2015\n    <\/p>\n<p>\n      A listing of the KEYTRUDA late-breaker, oral and poster sessions are<br \/>\n      included below:\n    <\/p>\n<p>\n      <span class=\"bwuline\">Late-Breaker Oral Presentations<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        (Abstract #18LBA) PD-L2 expression in human tumors: relevance to<br \/>\n        anti-PD-1 therapy in cancer. J. Yearley. Sunday, Sept. 27, 10:05 AM<br \/>\n        CEST. Location: Hall A1.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #24LBA) Safety data from the phase 1b part of the<br \/>\n        MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and<br \/>\n        pembrolizumab for unresectable stage IIIB-IV melanoma. G. Long.<br \/>\n        Sunday, Sept. 27, 12:00 PM CEST. Location: Hall A2.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #33LBA) Efficacy and safety of pembrolizumab (pembro;<br \/>\n        MK-3475) for patients (pts) with previously treated advanced non-small<br \/>\n        cell lung cancer (NSCLC) Enrolled in KEYNOTE-001. J.C. Soria. Monday,<br \/>\n        Sept. 28, 10:50 AM CEST. Location: Strauss.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #22LBA) Activity of PD-1 blockade with pembrolizumab as<br \/>\n        first systemic therapy in patients with advanced Merkel cell<br \/>\n        carcinoma. P. Nghiem. Sunday, Sept. 27, 11:30 AM CEST. Location: Hall<br \/>\n        A2.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\">Oral Presentations<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        (Abstract #2801) Antitumor activity and safety of pembrolizumab in<br \/>\n        patients with PD-L1\u2013positive nasopharyngeal carcinoma: Interim results<br \/>\n        from a phase 1b study. C. Hsu. Saturday, Sept. 26, 10:45 CEST.<br \/>\n        Location: Hall C1.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #500) Pembrolizumab (MK-3475) for PD-L1\u2013positive squamous<br \/>\n        cell carcinoma (SCC) of the anal canal: Preliminary safety and<br \/>\n        efficacy results from KEYNOTE-028. P. Ott. Sunday, Sept. 27, 5:05 PM<br \/>\n        CEST. Location: Hall D1.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #502) Pembrolizumab (MK-3475) for patients (pts) with<br \/>\n        advanced colorectal carcinoma (CRC): Preliminary results from<br \/>\n        KEYNOTE-028. B. O\u2019Neil. Sunday, Sept. 27, 5:35 PM CEST. Location: Hall<br \/>\n        D1.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\">Poster Sessions<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        (Abstract #507) Evaluation of patients with progressive metastatic<br \/>\n        head and neck cancer treated with PD-1 inhibition with pembrolizumab<br \/>\n        and radiation therapy: Assessment of local and systemic effects. T.Y.<br \/>\n        Seiwert. Saturday, Sept. 26, 4:45 PM-6:45 PM CEST. Location: Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #523) Initial clinical experience with pembrolizumab in<br \/>\n        metastatic heavily pre-treated patients with solid cancers in a single<br \/>\n        institution. R. Leibowitz-Amit. Saturday, Sept. 26, 4:45 PM-6:45 PM<br \/>\n        CEST. Location: Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #525) Safety and efficacy of pembrolizumab (MK-3475) in<br \/>\n        patients (pts) with advanced biliary tract cancer: Interim results of<br \/>\n        KEYNOTE-028. Y.J. Bang. Saturday, Sept. 26, 4:45 PM-6:45 PM CEST (5:15<br \/>\n        PM-6:15 PM CEST spotlight session). Location: Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #2860) Correlation between plasma Epstein-Barr virus DNA and<br \/>\n        clinical response to pembrolizumab in patients with advanced or<br \/>\n        metastatic nasopharyngeal carcinoma. H.F. Kao. Sunday, Sept. 27, 9:15<br \/>\n        AM-11:15 AM CEST. Location: Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #2866) Antitumor activity of the anti-PD-1 antibody<br \/>\n        pembrolizumab in subgroups of patients with recurrent\/metastatic head<br \/>\n        and neck squamous cell carcinoma (R\/M HNSCC): Exploratory analyses<br \/>\n        from KEYNOTE-012. L. Chow. Sunday, Sept. 27, 9:15 AM-11:15 AM CEST.<br \/>\n        Location: Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #3325) Safety and efficacy of pembrolizumab (MK-3475) for<br \/>\n        Japanese patients (pts) with advanced melanoma: Preliminary results<br \/>\n        from KEYNOTE-041 Phase 1b study. K. Yokota. Sunday, Sept. 27, 4:45<br \/>\n        PM-6:45 PM CEST. Location: Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #3344) Relationship between pembrolizumab exposure and<br \/>\n        efficacy\/safety in 1016 patients (pts) with advanced or metastatic<br \/>\n        melanoma. S.P. Kang. Sunday, Sept. 27, 4:45 PM-6:45 PM CEST. Location:<br \/>\n        Hall C.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #2622) A Phase I\/II study to assess the safety and efficacy<br \/>\n        of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with<br \/>\n        advanced renal cell carcinoma (aRCC). D.F. McDermott. Monday, Sept.<br \/>\n        28, 4:45 PM-6:45 PM CEST. Location: Hall C.\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a complete list of abstract titles,<br \/>\n      please visit the European Cancer Congress website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.europeancancercongress.org%2FScientific-Programme%2FSearchable-Programme%23anchorScpr&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.europeancancercongress.org%2FScientific-Programme%2FSearchable-Programme%23anchorScpr&amp;index=1&amp;md5=12a530781902a58fd90d4bfb9ea932f6\" rel=\"nofollow\"><span class=\"bwuline\">http:\/\/www.europeancancercongress.org\/Scientific-Programme\/Searchable-Programme#anchorScpr<\/span><\/a>.\n    <\/p>\n<p>\n      About KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab)\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that blocks the interaction<br \/>\n      between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1<br \/>\n      receptor and blocking the interaction with the receptor ligands,<br \/>\n      KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune<br \/>\n      response, including the anti-tumor immune response. KEYTRUDA is<br \/>\n      indicated for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Selected Important Safety Information for KEYTRUDA\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or<br \/>\n      3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%)<br \/>\n      patients, respectively, receiving KEYTRUDA. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia and<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA in cases of severe hyperglycemia until<br \/>\n      metabolic control is achieved.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients, consisting of one case of Grade<br \/>\n      2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis<br \/>\n      with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients<br \/>\n      for changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA: exfoliative dermatitis,<br \/>\n      uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial<br \/>\n      seizures arising in a patient with inflammatory foci in brain<br \/>\n      parenchyma, severe dermatitis including bullous pemphigoid, myasthenic<br \/>\n      syndrome, optic neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction. [W&amp;P, 5.6, p.6]\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued for adverse reactions in 9% of 411 patients.<br \/>\n      Adverse reactions, reported in at least two patients, that led to<br \/>\n      discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients. The most frequent<br \/>\n      serious adverse reactions, reported in 2% or more of patients, were<br \/>\n      renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in at least 20% of patients)<br \/>\n      were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash<br \/>\n      (29%), decreased appetite (26%), constipation (21%), arthralgia (20%),<br \/>\n      and diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      Our Focus on Cancer\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey&nbsp;\u2013&nbsp;from lab to clinic&nbsp;\u2013&nbsp;to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=32e6be6ad208d9dfd445ce08ddedda49\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      About Merck\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=86ed121a0b8bb0a2eb99fed6d48759a2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=85da13eff0c8847dbcc1a180b9044b05\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=81e1112f3bc0908f8b48eea9e0afa9b8\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2Fmerck&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=245eea7ab796c6480be1dfc7ddfa0a25\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the Company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the Company\u2019s s<br \/>\n      patents and other protections for innovative products; and the exposure<br \/>\n      to litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=0f8f8cfbb64413e75a9754a8d6f73001\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=1be2f0580a3f1d44d5248540ad82a26c\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><br \/>\n      and the Medication Guide for KEYTRUDA at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51184823&amp;newsitemid=20150921005390&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=f6a36cbbed971cc48eab3e7fd1c072fd\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150921005390r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>An Phan,        908-255-6325<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA \u00ae (pembrolizumab) across a broad range of advanced cancers will be presented at this year\u2019s European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this year\u2019s ECC \u2013 including four late-breaking oral presentations. First-time data looking at PD-L2 expression in multiple tumors to assess the potential value of this biomarker in patient responsiveness to anti PD-1 therapies will also be presented. With these and other presentations, data on the potential role of KEYTRUDA will have been presented in more than 17 different cancers. Studies accepted into this year\u2019s ECC program also include the investigation of KEYTRUDA monotherapy in anal cancer, biliary tract cancer, colorectal cancer, Merkel cell carcinoma (a type of skin cancer),<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745117","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA \u00ae (pembrolizumab) across a broad range of advanced cancers will be presented at this year\u2019s European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this year\u2019s ECC \u2013 including four late-breaking oral presentations. First-time data looking at PD-L2 expression in multiple tumors to assess the potential value of this biomarker in patient responsiveness to anti PD-1 therapies will also be presented. With these and other presentations, data on the potential role of KEYTRUDA will have been presented in more than 17 different cancers. Studies accepted into this year\u2019s ECC program also include the investigation of KEYTRUDA monotherapy in anal cancer, biliary tract cancer, colorectal cancer, Merkel cell carcinoma (a type of skin cancer),\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\\\/\",\"name\":\"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-09-21T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: &#8230;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/","og_locale":"en_US","og_type":"article","og_title":"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA \u00ae (pembrolizumab) across a broad range of advanced cancers will be presented at this year\u2019s European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this year\u2019s ECC \u2013 including four late-breaking oral presentations. First-time data looking at PD-L2 expression in multiple tumors to assess the potential value of this biomarker in patient responsiveness to anti PD-1 therapies will also be presented. With these and other presentations, data on the potential role of KEYTRUDA will have been presented in more than 17 different cancers. Studies accepted into this year\u2019s ECC program also include the investigation of KEYTRUDA monotherapy in anal cancer, biliary tract cancer, colorectal cancer, Merkel cell carcinoma (a type of skin cancer),","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:56+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/","name":"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-09-21T07:00:00+00:00","dateModified":"2025-11-07T06:24:56+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-pembrolizumab-development-program-to-be-presented-at-european-cancer-congress-2015-including-data-in-four-new-cancer-type\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Data in Nine Difficult-to-Treat Cancers from Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: &#8230;"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7523df22-a23b-4b99-9677-99e4ac79bb00","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Data-in-Nine-Difficult-to-Treat-Cancers-from-Mercks-KEYTRUDA-pembrolizumab-Development-Program-to-be-Presented-at-European-Cancer-Con-UU8V8.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745117\/revisions"}],"predecessor-version":[{"id":3674598,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745117\/revisions\/3674598"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745117"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}